Autobahn Therapeutics Reports Positive Phase 2 AMPLIFY-BD Results for Elunetirom in Bipolar Depression Autobahn Therapeutics, Inc., a biotechnology company developing restorative treatments for people living with neuropsychiatric disorders, announced the…
GreenMan Vision Study Finds Virtual Reality May Improve Cataract IOL Education and Patient Satisfaction GreenMan Vision, Inc. has announced the publication of a peer-reviewed, multi-center study evaluating InSightVR, a patient-specific…
Pattern Bioscience Receives FDA Breakthrough Device Designation for Urine ID/AST Panel Pattern Bioscience, a company developing rapid diagnostic technologies for bacterial infections, has announced that the U.S. Food and Drug…
Establishment Labs Presents New Breast Tissue Preservation Data and Expands Minimally Invasive Platform at WSEI Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company focused on advancing women’s…
Therapy Gains Ground as a Go-To Solution for Everyday Stress and Social Connection Modern Health, a global workplace mental health platform, has released new international research examining how employees use…
Alkermes Reports Positive Phase 1 Results for Investigational Orexin 2 Receptor Agonist ALKS 7290 in Adult ADHD Alkermes plc (Nasdaq: ALKS) has announced positive topline results from a Phase 1…
Iambic Launches Enchant v3 to Advance AI-Driven End-to-End Drug Discovery Iambic, a clinical-stage life science and technology company developing novel medicines through an artificial intelligence-driven platform, has unveiled Enchant v3,…
Merck’s KEYTRUDA QLEX Approved in Japan for Subcutaneous Use Across KEYTRUDA Indications Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced that Japan’s Ministry of Health,…
Medincell Partner Teva Presents New Data on Investigational Olanzapine LAI and UZEDY at Psych Congress 2026 Medincell’s partner Teva Pharmaceuticals presented new clinical and real-world data on two long-acting injectable…
Bristol Myers Squibb Reports Two-Year Data Showing Durable Sotyktu Efficacy in Psoriatic Arthritis Bristol Myers Squibb (NYSE: BMY) announced positive two-year results from the Phase 3 POETYK PsA-2 study and…
Novartis’ Cosentyx Receives Positive CHMP Opinion for Polymyalgia Rheumatica in Europe Novartis announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has…
Roche’s Ocrevus Gains Positive CHMP Opinion for Pediatric Multiple Sclerosis in Europe Roche (SIX: RO, ROP; OTCQX: RHHBY) announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for…